Baird Maintains Outperform on Medline, Lowers Price Target to $45
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Baird analyst Eric Coldwell maintains Medline (NASDAQ:MDLN) with a Outperform and lowers the price target from $57 to $45.
Baird analyst Eric Coldwell maintains Medline (NASDAQ:MDLN) with a Outperform and lowers the price target from $57 to $45.